Use of doxorubicin and trabectedin in low-grade endometrial stromal sarcoma: A case report
Our results highlight the potential role of this chemotherapy combination in hormonal therapy-resistant LG-ESS, a malignancy with limited systemic therapeutic options. This is the first reported case of LG-ESS achieving prolonged stable disease with doxorubicin-trabectedin therapy and trabectedin maintenance. Given the manageable toxicity profile and encouraging tumor control, further studies should explore its potential role in LG-ESS management.
Authors
- Reitan Ribeiro (ORCID: https://orcid.org/0000-0002-4323-3854)
- Lara Richer (ORCID: https://orcid.org/0000-0002-1150-3610)
- Xing Zeng (ORCID: https://orcid.org/0000-0001-8229-5903)
- Basile Tessier‐Cloutier (ORCID: https://orcid.org/0000-0001-8739-3879)
- Tuyet Nhung Ton Nu
- Lucy Gilbert (ORCID: https://orcid.org/0000-0001-8605-5472)
- Lili Fu (ORCID: https://orcid.org/0000-0003-2261-0902)
- Victoria Mandilaras (ORCID: https://orcid.org/0000-0002-4705-4562)
- Shuk On Annie Leung (ORCID: https://orcid.org/0000-0003-4110-7595)
- Délya Valcourt‐Gendron
- Laurence Bernard (ORCID: https://orcid.org/0000-0003-3780-0274)
Institutions
- McGill University Health Centre (CA)
- McGill University (CA)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.gore.2025.101988
- Citations
- 1
- Primary Topic
- Uterine Myomas and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.06